Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB)
IFINWIL®: now approved in Switzerland1 Nine out of 10 cases of neuroblastoma occur in children under the age of five2 The average survival rate of children with HRNB is only 50%2 UXBRIDGE, England, July 8, 2025 /PRNewswire/ — Norgine, a leading European specialty pharmaceutical company, is pleased to announce that Swissmedic has approved the registration of IFINWIL® […]



